Assurex Health, a Mason, OH-based personalized medicine company, secured $30m in equity financing.
Backers included new investors American Financial Group and Cross Creek Advisors and existing investors Cincinnati Children’s Hospital Medical Center, Sequoia Capital, Claremont Creek Ventures, Mayo Clinic, CincyTech, Allos Ventures and Danmar Capital.
The company intends to use the funds to support increased clinical adoption and development of its GeneSight® products.
Led by Virginia C. Drosos, President and Chief Executive Officer, Assurex Health provides healthcare providers with a solution for treatment decision support for behavioral health and chronic pain conditions.
Its GeneSight allows health care providers to make more precise treatment decisions based on how a patient’s unique genetic makeup affects their individual response to 38 FDA-approved medications for depression, posttraumatic stress disorder (PTSD), bipolar disorder, schizophrenia and/or other mental health conditions. It analyzes over 785,000 permutations of an individual’s genes and available medications, and presents the results in an actionable color-coded report available 36 hours after Assurex Health receives a patient’s cheek swab.
The company also offers financial assistance programs for patients who qualify.